X
Novo’s diabetes pill beats injections in head-to-head trials
https://pharmaphorum.com/news/novo-nordisks-success-with-oral-diabetes-drug/
Type 2 diabetes
Trulicity helps SGLT-2 patients lower blood sugar
New phase 3b trial results show Lilly’s Trulicity combined with an SGLT2 inhibitor failed to show any benefits above and beyond Trulicity’s blood glucose lowering.
Novo aims for GLP-1 sales growth in China
Novo expects Victoza and semaglutide to gain momentum.
Novo highlights key ‘hypo’ data from Tresiba at EASD
Novo hopes data will justify higher price compared with rival.
More data supports Jardiance lead in cardiovascular battle
Cardioprotective effect occurred in patients independently of blood sugar control
Novo’s semaglutide outperforms Lilly GLP-1 rival
If approved semaglutide could become set the standard for GLP-1 therapy
The Berlin Declaration – driving early action in type 2 diabetes
International initiative helps countries focus on best policies for overcoming diabetes.
1 2